EMA rejects Alzheimer’s drug Leqembi over safety concerns
Financial Times — July 26, 2024, 03:00 PM UTC
Summary: The European Medicines Agency has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen, due to concerns over rare brain swelling side effects. The committee's decision follows the drug's approval in the US, where it is projected to generate $154 million in revenue this year. Approximately 50 million people globally are affected by Alzheimer’s, with 6.9 million in the EU.
Article metrics
The article metrics are deprecated.
I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.